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Abstract: To determine the marginal bone loss and the survival, success and failure rates of narrow
dental implants, a systematic literature search was carried out in the MEDLINE (Pubmed), Cochrane,
Scopus, and Scielo databases for articles published between 2010 and 2021. The exclusion criteria were:
systematic reviews, case reports, expert opinions; animal studies; samples of less than 10 subjects;
follow-up periods of less than 36 months; smokers of minimum 10 cigarettes/day; and articles about
mini-implants for orthodontic anchorage. Meta-analyses were performed to assess marginal bone
loss and implant survival, success, and failure rates. Fifteen studies were included: 7 clinical trials,
3 randomized clinical trials, 3 cohort studies, and 2 case series. The total number of subjects was 773,
in whom 1245 implants were placed. The survival rate for the narrow diameter implants was 97%,
the success rate 96.8%, and the failure rate 3%. Marginal bone loss was 0.821 mm. All these data were
evaluated at 36 months. Based on the literature, it can be considered that there is sufficient evidence
to consider small diameter implants a predictable treatment option. These show favorable survival
and success rates and marginal bone loss. All of them are comparable to those of standard diameter
dental implants.
Keywords: diameter; narrow-diameter; dental implants; mini dental implants
1. Introduction
Oral rehabilitation with dental implants provides an increase in oral health and quality
of life [1,2]. Such a treatment has shown a success rates of up to 98% at 10 years [3], and
excellent treatment predictability, which is reflected in countless clinical studies [3–5].
Historically, implants have been used and documented mainly with diameters of 3.75 mm
and 4.1 mm, being considered standard diameter dental implants (SDI). The indications for
these implants have been numerous and treatment protocols have been established with
excellent long-term results [6]. However, a disadvantage of SDIs is that bone availability,
both of the alveolar ridge horizontally, as well as between tooth and tooth or tooth and
implant, is sometimes insufficient [7].
Alveolar ridge resorption begins immediately after tooth extraction and this process is
more intense during the first year, when about 60% of the thickness of the alveolar ridge is
resorbed [8,9]. In the mandible, ridge resorption is chronic, progressive and directly linked
to the duration of edentulism [10].
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In addition to the aforementioned, the reduction in bone width may be due to, or
aggravated by, other causes such as trauma, malformation, neoplasms, use of removable
prostheses and periodontal disease [11]. This causes challenging limitations for implant
placement. In these cases, surgical procedures may be necessary to increase insufficient
bone volume [11]. However, these procedures require surgical expertise to prevent possible
complications such as postoperative pain, infection, nerve damage, bone fractures, bleeding,
wound dehiscence, and implant failure. This greater morbidity, together with a high
economic cost and a longer surgical and healing time, raises the need for other therapeutic
options [11].
Likewise, it is considered that in medically compromised or elderly patients, regenera-
tive procedures carry a high risk of complications [12,13]. Therefore, alternative concepts,
such as narrow diameter dental implants (NDI) are leading to increased interest at the
clinical and scientific levels. As early as 2014, Schiegnitz et al. [12], indicated that avoiding
regenerative procedures or other invasive surgical treatments using NDI can expand treat-
ment options, avoid more invasive procedures, reducing patient morbidity and treatment
time [12].
The definition of NDI is not conclusive in published studies and there are several
classifications according to different authors. This review has been based on that described
by Klein et al. in 2014 [7] which distinguishes between three sub-categories: Category 1:
<3.0 mm (“mini-implants”); Category 2: 3.0–3.25 mm; Category 3: 3.30–3.50 mm.
The clinical evidence comparing the NDI with SDI creates controversy in the literature;
consequently, and based on the above, the objective of this systematic review is to determine
the survival, success and failure rates of the NDI placed in narrow bone compared to the
SDI placed in normal bone, as well as the peri-implant marginal bone loss.
2. Materials and Methods
2.1. Reporting Format
This systematic review has been prepared according to the PRISMA (Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis) criteria [14]. Before the systematic
search, a detailed protocol was developed on the methodology to be followed. The protocol
was not registered.
2.2. PICO (Population, Intervention, Comparison, Outcomes) Question
Population (P): Partially or totally edentulous patients; Intervention (I): Placement
of narrow dental implants in the mandible and/or maxilla; Comparison (C): Standard
diameter or larger diameter implants; Outcomes (O): Implant success, survival and failure
rates and marginal bone loss.
2.3. Eligibility Criteria
Inclusion criteria: (i) articles in which the main objective was to treat partially or totally
edentulous patients with narrow dental implants were considered; (ii) clinical trials, cohort
studies, and case series in healthy humans; (iii) published in the last 10 years in English
or Spanish; (iv) minimum 10 patients treated with NDI; (v) With a minimum follow-up
period of 36 months after implant placement. Exclusion criteria: (i) systematic reviews,
case reports, and expert opinions; (ii) animal studies; (iii) studies in which the sample was
less than 10 subjects; (iv) follow-up period of less than 36 months after implant placement;
(v) smokers of more than 10 cigarettes/day; (vi) mini-implants for orthodontic anchoring.
2.4. Search Strategy and Study Selection
An electronic search was carried out in the MEDLINE/PubMed, Cochrane, Scopus,
and Scielo databases for articles published between 2010 and 2020. The last search was
carried out on 5 March 2021.
The following keywords were used: small diameter, narrow-diameter, dental implants
and mini dental implants, combined through advanced search in the aforementioned
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databases: (((“small”[All Fields] AND diameter[All Fields]) OR narrow-diameter[All
Fields]) AND (“dental implants”[MeSH Terms] OR (“dental”[All Fields] AND “implants”[All
Fields]) OR “dental implants”[All Fields])) AND (mini[All Fields] AND (“dental im-
plants”[MeSH Terms] OR (“dental”[All Fields] AND “implants”[All Fields]) OR “dental
implants”[All Fields])).
All articles were initially identified by two experts Georgina González-Valls (G.G.V.)
and Juan Manuel Céspedes-Sánchez (J.M.C.S.). After reading the titles, the abstracts of
those that presented the potential of inclusion were read. Subsequently, the full texts of the
selected articles were read to verify that the inclusion criteria were met. Any discrepancies
during the selection process were resolved by one of the two authors Beatriz González-
Navarro (B.G.N.) or José López-López (J.L.L.).
2.5. Data Collection
The data were extracted by one of the authors Georgina González-Valls (G.G.V.) and
entered in a data collection form (Microsoft Excel version 16.44). A second author reviewed
the veracity of the collected data Elisabet Roca-Millan (E.R.M.). The following data were
extracted: authors, type of study, number of patients, gender, age, diameter and length
of the implants, location, type of restoration, follow-up time, number of failed implants,
implants survival and success rates, and marginal bone loss.
2.6. Quality Assessment and Risk of Bias
Version 2 of Cochrane Collaboration’s tool for assessing the risk of bias in randomized
trials (RoB 2) [15] was implemented to evaluate the risk of bias in the different domains of
the included randomized clinical trials. The domains evaluated from the studies were: ran-
dom sequence generation, allocation concealment, blinding of participants and researchers,
blinding of outcome assessment, incomplete outcome data, selective outcome reporting
and other sources of bias. Based on this, the studies were classified as ‘low risk’, unclear
risk’, and ‘high risk’.
The methodological index for non-randomized studies (MINORS) [16] was used to
assess the risk of bias of the non-randomized clinical trials and cohort studies. In the
MINORS scale, 12 categories were evaluated for comparative studies and 8 for studies that
do not have a control group.
2.7. Statistical Analysis
Different pooled estimates from the studies were obtained using the statistical analysis
software OpenMeta [Analyst] (Version 1, Brown University, Providence, RI, USA).
Binary and continuous random-effects models were used to calculate the weighted
proportions and means and the corresponding 95% confidence intervals (CI) among the
studies. The evaluated variables were the survival, success, and failure rates and the
marginal bone loss around dental implants, all at 36 months. Heterogeneity was assessed
based on a calculation of the I2 statistic and the level of significance was set at p < 0.05.
3. Results
3.1. Study Selection
A total of 971 articles were identified in the first search phase. During the second
phase and after reading the title of these, the systematic reviews, case reports, and expert
opinions were discarded and those that dealt with mini-implants for orthodontic anchorage
were also discarded; obtaining a total of 144 articles. Subsequently, the abstracts were read
and 45 articles were obtained. Finally, after reading the full text, 15 articles were included
in the review that met the established inclusion–exclusion criteria [17–31] (Figure 1).




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram of selection process.
3.2. Study Methods and Characteristics
Of the 15 articles included, 7 are clinical trials [17,19–22,27,31], 3 are randomized con-
trolled clinical trials [18,24,28], 3 are cohort studies [25,26,29] and 2 are a case series [23,30],
all of them published between 2010 and 2018 (Table 1).
The studies were carried out in 11 different countries: 2 in Belgium [17,24], 2 in
Egypt [18,19], 1 in England [20], 2 in Italy [21,22], 1 in Switzerland [23], 1 in Turkey [25], 2
in Saudi Arabia [26,27], 1 in Brazil [28], 1 in China [29], 1 in the United States [30] and 1 in
Spain [31].
The total number of patients included in the selected studies was 773 (359 men and
370 women). All papers included both men and women. The study by Al-Shibani et al. [27]
was the only one in which gender was not specified. The study with the largest number
of patients was Arisan et al. (N = 139) [25], while that of Moraguez et al. (N = 10) [23],
was the one with the fewest patients. The mean age was 44.8 years, range from 13 to
80 years. In 5 articles [18,20,21,26,28] the age range was not specified and the article by
Al-Aali et al. [26] was the only one in which the mean age was not specified.
The total number of implants was 1245. In all the studies except that of Galindo
Moreno et al. [31] the area where they were placed was specified, with 713 implants placed
in the mandible [17–22,24–30] and 433 in the maxilla [17,20–23,25,28–30]. All articles also
specified whether the implants were placed anteriorly or posteriorly; with 998 implants
placed in the anterior region [17–25,30,31] and 247 in the posterior region [26–29].
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2017 (17) CT 6 14 15.6 (13–19)
2 × 10; 13 30 MAX/MAND Single crowns inanterior sector 42 1; 96.6%; ND −1.09 ± 1.742.5 × 10; 13
Maryod et al.
2014 (18) RCT 20 16 64.1 1.8 × 15 120 MAND Overdenture 36 7; 94.2%; ND ND
Elsyad, et al.
2011 (19) CT 16 12 62.9 (49–75) 1.8 × 12; 18 112 MAND Overdenture 36 4; 96.4%; 92.90% −1.26 ± 0.64
King et al.
2016 (20) CT 18 20 24 3.0 × 11; 15 62 MAX/MAND
Single crowns in
anterior sector 36 2; 96.8%; ND −0.23
Maiorana et al.
2015 (21) CT 36 33 32 3.0 × 11; 15 97 MAX/MAND
Single crowns in
anterior sector 36 4; 95.9%; ND −0.09
Pieri et al.
2014 (22) CT 18 32 41.58 (19–64) 3.0 × 11; 15 50 MAX/MAND
Single crowns in
anterior sector 36 0; 100%; 100% −0.24 ± 0.15
Moraguez
et al. 2017 (23) CS 4 6 49.4 (32–68) 3.3 × 10; 12 20 MAX
Single crowns in
anterior sector 60 0;100%; ND −2.17 ± 0.38
Quirynen et al.




MAND Overdenture 36 2; 97.3%; 97.3% −0.6 ± 0.71
Arisan et al.
2010 (25) Cohort 66 73 55.3 (21–80)
3.3 × 8; 14, 9.5; 15 316 ND Overdenture;Single crowns in
anterior sector
124 14; 95.6%; 91.40%
−1.32 ± 0.13
maxilla
3.4 × 8; 14, 9.5; 15 −1.28 ± 0.14mandible
Al-Aali et al.
2018 (26) Cohort 43 35 ≥25 3.3 × 10; 12 102 MAND
Crowns posterior
sector 42 ND −1.17 ± 0.06
Al-Shibani
et al. 2018 (27) CT 44 41.6 (30–50) 3.3 × 10 25 MAND
Crowns posterior
sector 36 0; 100%; ND 0.15 (0.1–0.4)
De Souza et al.
2017 (28) RTC 10 12 59.2 3.3 × 6; 12 22 MAX/MAND
Crowns posterior
sector 36 0; 100%; 95% −0.58 ± 0.39
Yu-Shi et al.
2017 (29) Cohort 38 29 35.6 (21–56) 3.3 × 10; 12 98 MAX/MAND
Crowns posterior
sector 121 3; 96.9%; ND −1.19 ± 1.07
Froum et al.
2017 (30) CS 6 8 48.6 (23–87)
1.8 × 7; 10; 14
19 MAX/MAND Single crowns inanterior sector 137
0; 100%; 84% −0.162.2 × 7; 10; 14




CT 36 33 32.5 (18–72) 3 × 11; 13; 15 97 MAX/MAND Single crowns inanterior sector 60 4; 92.8%; ND −0.15
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In all articles the diameter and length of the implants used are detailed. Four arti-
cles [17–19,30] used implants of less than 3.0 mm, four articles [20–22,31] between 3 and
3.25 mm, and seven articles [23–29] used implants between 3.3 and 3.5 mm. The most
widely used diameters were those in the 3.3 to 3.5 mm category, with a total of 658 im-
plants [23–29]. The next most used category was 3 to 3.25 mm with 306 implants [20–22,31]
and lastly those of less than 3 mm with 281 implants [17–19,30] (Figure 2A). The mean
length of the implants used was 12.3 mm (range 8 to 18 mm).
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risk of bias. However, Quirynen et al. [24] does not specify the “Blinding of outcome assess-
ment”. Maryod et al. [18] have an overall unclear risk of bias. Also it has a high risk of bias 
in “Blinding of outcome assessment” and an unclear risk of bias in “Blinding of participants 
and researchers”. 
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Figure 2. (A) Classification of i pla ts accor i g to ia eter. ( ) Classification of implants according
to the indication.
The main indica ion for NDIs in the reviewed studies was for anterior sector rehabili-
tation with single crowns [17,20–23,25,30,31]. A total of 533 implants were used in this area.
The second most prevalent indication was rehabilitation with overdentures [18,19,24,25]
with a total of 465 implants used and, finally, 247 implants were used in the rehabilitation
of the posterior sector [26–29] (Figure 2B).
The mean follow-up time was 58 months from implant placement (range 36 to
137 months).
3.3. Quality Assessment and Risk of Bias
The present systematic review meets 24 of the 27 PRISMA criteria [14].
Table 2 shows the risk of bias of the three randomized clinical trials (RCTs) [18,24,28]
according to the RoB 2 tool. Quirynen et al. [24] and de Souza et al. [28] have an overall
low risk of bias. However, Quirynen et al. [24] does not specify the “Blinding of outcome
assessment”. Maryod et al. [18] have an overall unclear risk of bias. Also it has a high risk
of bias in “Blinding of outcome assessment” and an unclear risk of bias in “Blinding of
participants and researchers”.
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Of the 15 articles included in the present review, seven of them were NRCT [17,19–22,27,31]
and three were cohorts [25,26,29], all of th m evaluat d acc rding to th Minors s ale
(Table 3). Only on stu y [27] had a nt ol gr up. Th mean score bt ined fr m n-
comparativ arti les on th MINORS cale has been 11.8 poi s ut of a total of 16, eing
Galindo-Mo e o et al. [31] the arti le th t has obt in d th l west sc e with 10 points.
Lambert et al. [17], Elsyad et al. [19] nd Al-A li e . [26] ve bee the ar icl t
have obtained the maximum score of 13 points. Finally, Al-Shibani et al. [27] was the
only comparative article. In this, a total of 12 items were evaluated, obtaining 15 points
out of 24.
3.4. Marginal Bone Loss
Marginal bone loss was evaluated in all the articles except those by Lambert. et al. [17]
and Maryod et al. [18]. Since most of the included studies had a follow-up period of
36 months or more, marginal bone loss was assessed up to this point in time. Six of the
articles [19,22–24,28,31] could be included in the meta-analysis. A marginal bone loss of
0.821 mm was obtained (95% CI: 0.181–1.460; p = 0.012). Heterogeneity tests from pooled
showed statistical significance (I2 = 99.451%, p < 0.001). Galindo Moreno et al. [31] obtained
the least bone loss at 36 months with 0.110 mm. The diameter of the implants used was
3 mm. The study that recorded the greatest bone loss was that of Moraguez et al. [23] with
2.130 mm. The implants used had a diameter of 3.3 mm (Figure 3).
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3.5. Failure, Success, and Survival Rates
Both the survival rate and the implant failure rate were described by all the stud-
ies except that of Al-Aali et al. [26]. However, the success rate was only evaluated in
six of the 16 articles [19,22,24,25,28,30]. Meta-analyses were performed to assess these
rates at 36 months. The survival rate was 97% (95% CI: 95.7%–98.3%; p < 0.001) with
no significant difference regarding the heterogeneity of the included studies (I2 = 0%,
p = 0.773) [18–22,24,27,28,31] (Figure 4). The failure rate obtained was 3% (95% CI:
1.7%n−4.3%; p < 0.001) without significant heterogeneity (I2 = 0%, p = 0.773 [18–22,24,27,28,31]
(Figure 5). Only 4 articles evaluated the success rate at 36 months, with an estimated
mean value of 96.8% (95% CI: 94% −99.6%; p < 0.001) and without statistically significant
heterogeneity (I2 = 41.239 %, p = 0.164) [19,21,24,28] (Figure 6).
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4. Discussion 
NDIs are a valid treatment option that allows us to avoid more invasive procedures 
and higher morbidity. Patient preferences for minimally invasive treatment options, such 
as rehabilitation without bone augmentation, are generally high [32]. Therefore, this re-
view aims to determine the survival and success rates of NDIs compared to SDIs. 
Survival rates for NDIs are similar to those for SDIs. We place the survival rate of 
those between 96.7% and 99% [32]. Safii et al. [33] in 2010 stated the survival rate of SDI 
of 96.7% and Kim et al. [3] in 2018 of 98%. In the present review, most studies report fig-
ures for NDIs greater than 95% survival, and no study reports figures below 94.2%, with 
the mean survival rate at 36 months being 97% [18–22,24,27,28,31]. Reviewing the survival 
rates of implants associated with horizontal bone regeneration techniques, a survival of 
96.2% [34,35] was obtained in the “Split crest technique” and of 98% when it was regener-
ated with autologous bone blocks or guided bone regeneration. These data suggest that 
treatment with NDI is a valid and safe therapeutic option that allows obtaining results 
similar to bone regeneration techniques. 
When planning treatment with NDI, it is important to take into account factors such 
as its indications, the success of these, and the changes in bone remodeling that they may 
undergo, in addition to survival figures. 
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i re 6. Success rate at 36 months.
4. Discussion
NDIs are a valid treatment option that allows us to avoid more invasive procedures
and higher morbidity. Patient preferences for minimally invasive treatment options, such
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as rehabilitation without bone augmentation, are generally high [32]. Therefore, this review
aims to determine the survival and success rates of NDIs compared to SDIs.
Survival rates for NDIs are similar to those for SDIs. We place the survival rate of
those between 96.7% and 99% [32]. Safii et al. [33] in 2010 stated the survival rate of SDI
of 96.7% and Kim et al. [3] in 2018 of 98%. In the present review, most studies report
figures for NDIs greater than 95% survival, and no study reports figures below 94.2%,
with the mean survival rate at 36 months being 97% [18–22,24,27,28,31]. Reviewing the
survival rates of implants associated with horizontal bone regeneration techniques, a
survival of 96.2% [34,35] was obtained in the “Split crest technique” and of 98% when it
was regenerated with autologous bone blocks or guided bone regeneration. These data
suggest that treatment with NDI is a valid and safe therapeutic option that allows obtaining
results similar to bone regeneration techniques.
When planning treatment with NDI, it is important to take into account factors such
as its indications, the success of these, and the changes in bone remodeling that they may
undergo, in addition to survival figures.
Most of the articles [19,21,25,30] take into account the criteria of Albrektsson et al. [36]:
the implant is immobile when clinically evaluated, there is no evidence of radiolucency
around it, the average vertical bone loss is less than 0.2mm per year, absence of pain,
discomfort, or infection attributable to the implant, an implant design that allows the
placement of a crown or prosthesis with a satisfactory appearance for both the patient and
the dentist and a success rate of 85% at 5 years and 80% at 10 years [36]. One article [24]
takes into account the criteria of Buser et al. [37], and another one [28] takes into account
the criteria of Klein et al. [7] to determine the success of the implants. The success rate of the
NDI described in our review is 96.8% at 3 years [18,28]. These results are similar to those
obtained in implant placement procedures with simultaneous horizontal regeneration.
Bassetti et al. [34] obtained a success rate of 88.2% to 100% and Waechter et al. [35] of 98.5%,
both with the “Split crest technique”.
To date, there has been a lack of randomized clinical studies comparing the sur-
vival and success of NDI with that of SDI in regenerative procedures in situations of
severe atrophy. Failed implants were those that presented significant mean bone loss,
peri-implant radiolucency, mobility, infection, pain, discomfort, or that caused by sen-
sorineural alteration. Forty-one implants out of a total of 1245 failed, the failure rate is 3%
at 3 years [18–22,24,27,28,31]. Values very similar to those reported in other reviews [8,38].
The main reasons for failure were: infection [21,31], pain [18,25], and mobility [18,31].
Lemos et al. [39] stated in 2016 the failure rate of SDI of 2.72%.
Marginal bone loss over time is another important factor influencing the predictability
of treatment. Assaf et al. [40], suggested that the predictability of the implant is not only
related to its diameter but also the loss of marginal bone. These parameters should be
within the same limits as those reported for SDIs. The acceptable bone loss established in
the literature is 2 mm in the first year after loading the SDI, followed by a maximum of
0.2 mm per year [41,42]. Saffi et al. [33] reported the mean bone loss of SDI in 0.79 mm.
It is noteworthy that the studies included in our review showed peri-implant bone loss
comparable to that of SDIs. The mean bone loss reported in our review is 0.821 mm (CI:
0.181 to 1.460 mm) [19,22–24,28,31] at the end of the follow-up period (36 months), slightly
higher than that of the SDIs, 0.695 mm at 3 years [43].
The NDIs were mostly used for restorations in the anterior sector, mainly upper lateral
incisors or lower incisors. These locations usually have limited interdental space and a thin
alveolar ridge. Placing an implant too close to an adjacent tooth can lead to interproximal
bone loss, a factor that can negatively affect the final position of the papilla and the soft
tissues at the supracrestal level [20]. Therefore, in the anterior sector, the aesthetics and
stability of the peri-implant soft tissues are the main focuses of interest, in addition to
the survival of the implant. King et al. [20] indicated that using NDI, soft tissue stability
was achieved and clinically insignificant changes occurred in probing depth and gingival
zenith level.
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Overdentures as rehabilitation in edentulous jaws and with severe atrophy are another
of the most frequent indications before the NDI. These are indicated in those cases in which
we do not have enough bone to place an SDI and we do not want to perform any bone
regeneration procedure. Therefore, we must be aware that NDIs are normally inserted in
very atrophic edentulous jaws, which represents very challenging surgical situations [38].
Occlusion forces must also be considered. NDIs present limitations in certain clinical
situations, such as in patients with bruxism [19].
Survival, success, and marginal peri-implant bone loss rates obtained in our review
are similar to those of other reviews by other authors. The 97% survival obtained in our
review is slightly higher than that obtained by other authors: 95.6% [7] and 96.5% [38].
The success obtained of 96.8% is higher than that obtained by Klein et al. [7] of 93.7% and
comparable to that obtained by Schiegnitz et al. [38] of 96.2%. Regarding the peri-implant
marginal bone loss obtained in our review (0.821 mm), it is comparable and slightly lower
than that obtained by Schiegnitz et al. [38] of 0.993 mm and greater than that obtained by
Klein et al. [7] of 0.53 mm.
The main limitation of this systematic review is the heterogeneity of the different
articles included in terms of study design, follow-up period, sample size, and type of
prosthetic rehabilitation. Some articles do not provide data on marginal bone loss, and
others do not evaluate the success rate, or the data they provide is not sufficient to include
them in the meta-analysis.
5. Conclusions
Based on the results obtained in this review, it can be stated that NDIs are a predictable
treatment option. This is due to their favorable survival, success, and average bone loss
rates. All of them are comparable to those of the SDI or those of regenerative bone treat-
ments at a horizontal level and bone expansion techniques. Therefore, it can be concluded
that NDIs are a valid therapeutic option in cases in which there is not enough bone volume
in the horizontal direction to place an SDI. NDIs are a viable option in medically compro-
mised or elderly patients to avoid more invasive procedures, thus reducing morbidity and
treatment time.
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